SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

26 Sep 2012 16:01

RNS Number : 2489N
Genus PLC
26 September 2012
 



26 September 2012

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholdings

 

 

Genus announces that 21,008 ordinary shares of 10 pence each in the Company ("Share(s)") were today sold on behalf of John Worby, Group Finance Director, at a price of 1,474.68 pence per Share. This sale was made further to the vesting of 42,017 conditional nil-cost Share options on 17 September 2012 under the Company's Performance Share Plan ("the PSP") and represents the exercise by John Worby of one half of his vesting entitlement. The remaining 21,009 Share options that vested under the PSP in September 2012 have been retained by John Worby and have not been exercised.

 

John Worby's direct shareholding in the Company stands at 10,000 Shares, representing 0.02% of the issued share capital of the Company that is currently 60,354,170 Shares. In addition, he is the owner of 64,271 nil-cost Share options that have vested under the PSP and he remains the beneficial owner of 68,360 conditional nil-cost Share options under the PSP.

 

Genus also announces that:

 

(i) 3,619 Shares were today sold on behalf of Bill Christianson, Chief Operating Officer, Genus PIC, at a price of 1,474.68 pence per Share. This sale was made further to the vesting of 18,970 market value Share options on 17 September 2012 under the Company's Executive Share Option Plan ("the ESOP"). Bill Christianson's direct shareholding in the Company stands at 6,932 Shares representing 0.01% of the issued share capital of the Company. In addition, he remains the beneficial owner of 56,953 conditional nil-cost Share options under the PSP.

 

(ii) 2,354 Shares were today sold on behalf of Ricardo Campos, Chief Operating Officer, Genus ABS, at a price of 1,474.68 pence per Share. This sale was made further to the vesting of 8,466 market value Share options on 17 September 2012 under the ESOP. Ricardo Campos has no direct shareholding in the Company and is the owner of 4,233 market value Share options that have vested under the ESOS and the beneficial owner of 38,696 conditional market value Share options under the ESOS.

 

(iii) 5,184 Shares were today sold on behalf of Jerry Thompson, Chief Operating Officer, Genus Asia, at a price of 1,474.68 pence per Share. This sale was made further to the vesting of 18,640 market value Share options on 17 September 2012 under the ESOP. Jerry Thompson has no direct shareholding in the Company and is the owner of 9,320 market value Share options that have vested under the ESOS and he is the beneficial owner of 21,452 conditional nil-cost Share options under the PSP and 17,545 conditional market value Share options under the ESOS

 

(iv) 10,499 Shares were today sold on behalf of Denny Funk, Chief Scientific Officer, at a price of 1,474.68 pence per Share. This sale was made further to the vesting of 18,878 market value Share options on 17 September 2012 under the ESOP. Denny Funk has no direct shareholding in the Company and is the beneficial owner of 25,568 market value Share options under the ESOS.

 

(v) 22,154 Shares were today sold on behalf of Ian Farrelly, Group Company Secretary & General Counsel, at a price of 1,474.68 pence per Share. This sale was made further to the vesting of 22,154 nil-cost Share options on 17 September 2012 under the PSP. Ian Farrelly has no direct shareholding in the Company and is the beneficial owner of 39,308 nil-cost Share options under the PSP.

 

(vi) 19,404 Shares were today sold on behalf of David Crosby, Group Financial Controller, at a price of 1,474.68 pence per Share. This sale was made further to the vesting of 19,404 nil-cost Share options on 17 September 2012 under the PSP. David Crosby has no direct shareholding in the Company and is the beneficial owner of 34,439 nil-cost Share options under the PSP.

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUNVSRUKAKUAR
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.